ITP
MCID: THR001
MIFTS: 59

Thrombocytopenia Due to Platelet Alloimmunization (ITP)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 12 15 73
Immune Thrombocytopenia 12 76 53 25 37 15 63
Autoimmune Thrombocytopenia 25 29 55 73
Immune Thrombocytopenic Purpura 25 73
Thrombocytopenia Due to Immune Destruction 12
Idiopathic Thrombocytopenic Purpura 25
Autoimmune Thrombocytopenic Purpura 25
Auto-Immune Thrombocytopenia 12
Werlhof Disease 25
Itp 25

Classifications:



External Ids:

Disease Ontology 12 DOID:1587
NCIt 50 C3991
SNOMED-CT 68 2897005
KEGG 37 H01240

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

PubMed Health : 63 About immune thrombocytopenia: Immune thrombocytopenia (THROM-bo-si-toe-PE-ne-ah), or ITP, is a bleeding disorder. In ITP, the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets (PLATE-lets) or thrombocytes (THROM-bo-sites).Platelets are made in your bone marrow along with other kinds of blood cells. They stick together (clot) to seal small cuts or breaks on blood vessel walls and stop bleeding.

MalaCards based summary : Thrombocytopenia Due to Platelet Alloimmunization, also known as immune thrombocytopenia, is related to amegakaryocytic thrombocytopenia, congenital and purpura. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Phagosome and Osteoclast differentiation. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 76 Immune thrombocytopenia (ITP) is a type of thrombocytopenic purpura defined as isolated low platelet... more...

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia Ankrd26-Related Thrombocytopenia
Myh9 Related Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 444)
# Related Disease Score Top Affiliating Genes
1 amegakaryocytic thrombocytopenia, congenital 31.8 MPL THPO
2 purpura 31.8 ITGA2B ITGB3 MPL THPO
3 thrombocytopenic purpura, autoimmune 31.8 FCGR2C ITGA2B ITGB3 MPL SELP THPO
4 thrombocytosis 30.0 MPL SELP THPO
5 polycythemia vera 29.9 ITGB3 MPL SELP THPO
6 thrombocytopenia 29.8 GP9 ITGA2 ITGA2B ITGB3 MPL MYH9
7 essential thrombocythemia 29.7 ITGA2B ITGB3 MPL SELP THPO
8 clopidogrel resistance 29.5 ITGB3 SELP
9 bernard-soulier syndrome 29.3 GP9 ITGA2 ITGA2B ITGB3 MYH9 THPO
10 thrombasthenia 29.1 GP9 ITGA2 ITGA2B ITGB3 SELP
11 blood platelet disease 28.9 GP9 ITGA2B ITGB3 MPL MYH9 SELP
12 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 12.1
13 sea-blue histiocyte disease 11.7
14 immunodeficiency, common variable, 8, with autoimmunity 11.5
15 ras-associated autoimmune leukoproliferative disorder 11.4
16 spondyloenchondrodysplasia 11.3
17 purine nucleoside phosphorylase deficiency 11.0
18 inosine triphosphatase deficiency 11.0
19 autoimmune lymphoproliferative syndrome due to ctla4 haploinsuffiency 11.0
20 antiphospholipid syndrome, familial 11.0
21 hepatitis 10.4
22 myelodysplastic syndrome 10.2
23 colitis 10.2
24 hemolytic anemia 10.2
25 thrombosis 10.2
26 stroke, ischemic 10.2
27 ulcerative colitis 10.2
28 nocardiosis 10.2
29 thrombocytopenia 3 10.2 MPL THPO
30 thrombocythemia 1 10.2 MPL THPO
31 helicobacter pylori infection 10.2
32 autoimmune hepatitis 10.2
33 common variable immunodeficiency 10.2
34 thrombotic thrombocytopenic purpura 10.2
35 rabies 10.2
36 hepatitis c 10.2
37 viral infectious disease 10.2
38 cytomegalovirus infection 10.2
39 dyskeratosis congenita, autosomal dominant 6 10.2 MPL THPO
40 bleeding disorder, platelet-type, 16 10.2 ITGA2B ITGB3
41 aspirin resistance 10.1 ITGA2 ITGB3
42 breast cancer 10.1
43 multiple sclerosis 10.1
44 renal cell carcinoma, nonpapillary 10.1
45 aspergillosis 10.1
46 mononeuropathy 10.1
47 histiocytosis 10.1
48 influenza 10.1
49 herpes simplex 10.1
50 systemic lupus erythematosus 10.1

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CD19 FCGR2A FCGR2B FCGRT GP9 IL17A
2 homeostasis/metabolism MP:0005376 9.9 CD19 FCGR2B FCGRT IL17A ITGA2 ITGA2B
3 immune system MP:0005387 9.7 CD19 FCGR2A FCGR2B FCGRT IL17A ITGA2B
4 renal/urinary system MP:0005367 9.1 CD19 FCGR2B IL17A ITGB3 MYH9 SELP

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

PubMedHealth treatment related to Thrombocytopenia Due to Platelet Alloimmunization: 63

Treatment for immune thrombocytopenia (ITP) is based on how much and how often you're bleeding and your platelet count.Adults who have mild ITP may not need any treatment, other than watching their symptoms and platelet counts. Adults who have ITP with very low platelet counts or bleeding problems often are treated.The acute (short-term) type of ITP that occurs in children often goes away within a few weeks or months. Children who have bleeding symptoms, other than merely bruising (purpura), usually are treated.Children who have mild ITP may not need treatment other than monitoring and followup to make sure their platelet counts return to normal.

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 1177-87-3
3
rituximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 174722-31-7 10201696
4
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
5
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
6
Hydroxychloroquine Approved Phase 4 118-42-3 3652
7
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613
9
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
10
alemtuzumab Approved, Investigational Phase 4,Phase 2 216503-57-0
11
Caffeic acid Experimental, Investigational Phase 4,Phase 3 331-39-5 1549111
12 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
13 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
15 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
16 glucocorticoids Phase 4,Phase 2,Phase 3
17 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1
18 Autonomic Agents Phase 4,Phase 2,Phase 3
19 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
20 Hormones Phase 4,Phase 2,Phase 3,Phase 1
21 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
22 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
23 BB 1101 Phase 4,Phase 2,Phase 3
24 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
25 Antiemetics Phase 4,Phase 2,Phase 3
26
protease inhibitors Phase 4,Phase 2,Phase 3
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Antiparasitic Agents Phase 4,Phase 3
32 Antiprotozoal Agents Phase 4,Phase 3
33 Antineoplastic Agents, Phytogenic Phase 4
34 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
35 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
36 Antimalarials Phase 4,Phase 3
37 Antimitotic Agents Phase 4
38 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
40 Proton Pump Inhibitors Phase 4,Phase 3
41 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 1,Phase 2
42 Hypolipidemic Agents Phase 4,Phase 1,Phase 2
43 Atorvastatin Calcium Phase 4,Phase 1,Phase 2 134523-03-8
44 Lipid Regulating Agents Phase 4,Phase 1,Phase 2
45 Anticholesteremic Agents Phase 4,Phase 1,Phase 2
46 Bone Density Conservation Agents Phase 4
47 Calcium, Dietary Phase 4,Phase 1,Phase 2
48 Tin Fluorides Phase 4
49 Cytochrome P-450 CYP3A Inhibitors Phase 4
50 Cytochrome P-450 Enzyme Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 144)
# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
3 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
4 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
5 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
6 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
7 The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
8 Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
9 Atorvastatin in Management of Newly Diagnosed ITP Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
10 Immunomodulation With Romiplostim in Young Adults With ITP Recruiting NCT02760251 Phase 4 romiplostim
11 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
12 Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 Active, not recruiting NCT02255656 Phase 4 alemtuzumab GZ402673
13 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
14 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
15 Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
16 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy Unknown status NCT02270801 Phase 3 rhTPO
17 A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
18 Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP Unknown status NCT01805648 Phase 3 rhTPO
19 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
20 DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
21 Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients Unknown status NCT02877212 Phase 3 Eltrombopag
22 Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) Completed NCT01438840 Phase 3 Avatrombopag;Placebo;Standard of care
23 Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) Completed NCT02868099 Phase 3 Romiplostim;Placebo
24 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
25 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients Completed NCT01444417 Phase 3 Romiplostim;Placebo
26 An Investigation of rhTPO With Different Frequencies in the Management of ITP Completed NCT02139501 Phase 3 Recombinant Human Thrombopoietin (rhTPO)
27 Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia Completed NCT01349790 Phase 3 NewGam
28 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia Completed NCT02334813 Phase 3 Prednisone;Dexamethasone
29 Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) Completed NCT01506414 Phase 3 rhTPO in combination with Rituximab
30 Caffeic Acid Tablets as a Second-line Therapy for ITP Completed NCT02351622 Phase 3 Caffeic acid;Dexamethasone;Placebo
31 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. Completed NCT01520909 Phase 3 Eltrombopag;Placebo
32 rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP Completed NCT01734044 Phase 3 recombinant human thrombopoietin (rhTPO); dexamethasone;Dexamethasone
33 Rituximab as Second Line Treatment for ITP Completed NCT00344149 Phase 3 Rituximab (Mabthera)
34 Eltrombopag Phase III Study In Chinese Chronic ITP Patients Completed NCT01762761 Phase 3 eltrombopag;placebo
35 rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP Completed NCT01525836 Phase 3 rituximab; recombinant human thrombopoietin (rhTPO);Rituximab
36 A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. Completed NCT00376077 Phase 3 Methylprednisolone and IVIG;Placebo and IVIG
37 Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia Recruiting NCT03520049 Phase 3 Oseltamivir;Placebo
38 Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate Recruiting NCT03156452 Phase 3 Mycophenolate Mofetil;Prednisolone
39 This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP) Recruiting NCT02859909 Phase 3
40 Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Recruiting NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
41 The PROLONG Trial - Rituximab Maintenance Therapy in ITP Recruiting NCT03010202 Phase 3 Dexamethasone;Rituximab
42 A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients Recruiting NCT01621204 Phase 3 Eltrombopag;IVIG infusion
43 H. Pylori Eradication for Moderate ITP Recruiting NCT03177629 Phase 3 treatment : H. pylori eradication
44 Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML Recruiting NCT03701217 Phase 2, Phase 3 Eltrombopag
45 A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Active, not recruiting NCT03164915 Phase 3
46 Single Arm, Open-label, Long-term Study of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP. Active, not recruiting NCT02279173 Phase 3 Romiplostim
47 Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia Not yet recruiting NCT03492515 Phase 3 recombinant human thrombopoietin;Platelet Concentrate
48 Rituximab Combining Bortezomib Versus Rituximab in Management of ITP Not yet recruiting NCT03443570 Phase 3 Rituximab;Bortezomib
49 Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP Not yet recruiting NCT03252457 Phase 3 Decitabine;Dexamethasone
50 The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP) Terminated NCT01226524 Phase 2, Phase 3 Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 29 FCGR2C

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

41
Bone, Bone Marrow, T Cells, B Cells, Myeloid, Testes, Thyroid

Publications for Thrombocytopenia Due to Platelet Alloimmunization

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 1166)
# Title Authors Year
1
Association of cytotoxic T-lymphocyte antigen 4 gene with immune thrombocytopenia in Chinese Han children. ( 30319055 )
2019
2
Increased GPIbα shedding from platelets treated with immune thrombocytopenia plasma. ( 30445311 )
2019
3
Role of antithyroid autoimmunity as a predictive biomarker of chronic immune thrombocytopenia. ( 30270575 )
2019
4
Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis. ( 29402802 )
2018
5
Reduced PTEN involved in primary immune thrombocytopenia via contributing to B cell hyper-responsiveness. ( 29175594 )
2018
6
Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-I_B/SMAD pathway in patients with immune thrombocytopenia. ( 29327472 )
2018
7
IL-10 polymorphisms and T-cell subsets could affect the clinical presentation and outcome of childhood immune thrombocytopenia in Egyptian population. ( 29696721 )
2018
8
Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. ( 29357781 )
2018
9
Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus. ( 29380254 )
2018
10
Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. ( 29442265 )
2018
11
Subacute sclerosing panencephalitis and immune thrombocytopenia: More than a coincidence? ( 29407001 )
2018
12
Thrombopoietin and its receptor expression in pediatric patients with chronic immune thrombocytopenia. ( 29313460 )
2018
13
Diminished expression of I^2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. ( 29350259 )
2018
14
Immune dysregulation in primary immune thrombocytopenia patients. ( 29409398 )
2018
15
Immune Thrombocytopenia in a Child With Refractory Langerhans Cell Histiocytosis Following Cladribine Containing Therapy. ( 29889804 )
2018
16
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. ( 29978577 )
2018
17
Intravenous immunoglobulin versus observation in childhood immune thrombocytopenia: a randomized controlled trial. ( 29945954 )
2018
18
Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. ( 29330464 )
2018
19
A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up. ( 29516627 )
2018
20
Severe immune thrombocytopenia in pregnancy treated with Eltrombopag - A case report. ( 29981476 )
2018
21
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. ( 29978544 )
2018
22
Adult Primary Immune Thrombocytopenia: Spleen Histology Findings and Outcomes According to Rituximab Use Based on Analysis of 41 Cases. ( 29200102 )
2018
23
Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis: A case report and literature review. ( 30235659 )
2018
24
Chronic Thromboembolic Pulmonary Hypertension and Antiphospholipid Syndrome with Immune Thrombocytopenia: A Case Report. ( 30337514 )
2018
25
Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series. ( 29673280 )
2018
26
Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center. ( 29580123 )
2018
27
Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature. ( 30537439 )
2018
28
The association of hyperthyroidism and immune thrombocytopenia: Are we still missing something? ( 30069130 )
2018
29
Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia. ( 29081253 )
2018
30
Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. ( 29683946 )
2018
31
Severe rifamycin-induced immune thrombocytopenia in a patient with extra-pulmonary tuberculosis. ( 30236196 )
2018
32
Paving the way for improved management of severe immune thrombocytopenia purpura in pregnancy. ( 28724194 )
2018
33
Ovarian teratoma: yet another cause of immune thrombocytopenia. ( 30323687 )
2018
34
Akt-mediated platelet apoptosis and its therapeutic implications in immune thrombocytopenia. ( 30337485 )
2018
35
Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. ( 30341143 )
2018
36
Eltrombopag-based combination treatment for immune thrombocytopenia. ( 30344993 )
2018
37
Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature. ( 30373491 )
2018
38
Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study. ( 30384039 )
2018
39
CCR6 defines a subset of activated memory T cells of Th17 potential in immune thrombocytopenia. ( 30403287 )
2018
40
Low mucosal-associated invariant T-cell number in peripheral blood of patients with immune thrombocytopenia and their response to prednisolone. ( 30408105 )
2018
41
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients. ( 30408157 )
2018
42
Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score. ( 30409773 )
2018
43
Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study. ( 30417939 )
2018
44
Health-related quality of life in adult primary immune thrombocytopenia. ( 30444433 )
2018
45
Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. ( 30446804 )
2018
46
Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA. ( 30459507 )
2018
47
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. ( 30464563 )
2018
48
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia. ( 30464564 )
2018
49
Cytokine Profile, Apoptosis, Glucocorticoid Receptor, and P-glycoprotein Expression Before and After Megadose Methylprednisolone Treatment in Children With Acute Immune Thrombocytopenia. ( 30499912 )
2018
50
How do we diagnose immune thrombocytopenia in 2018? ( 30504358 )
2018

Variations for Thrombocytopenia Due to Platelet Alloimmunization

Expression for Thrombocytopenia Due to Platelet Alloimmunization

Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to KEGG:

37
# Name Kegg Source Accession
1 Phagosome hsa04145
2 Osteoclast differentiation hsa04380
3 Fc gamma R-mediated phagocytosis hsa04666

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.16 GP9 ITGA2 ITGA2B ITGB3 MPL SELP
2
Show member pathways
12.93 FCGR2A FCGR2B ITGA2 ITGA2B ITGB3 THPO
3 12.48 ITGA2 ITGA2B ITGB3 MYH9
4
Show member pathways
12.24 ITGA2 ITGA2B ITGB3 THPO
5 12.08 FCGR2A FCGR2B FCGR2C
6
Show member pathways
12.06 ITGA2 ITGA2B ITGB3
7
Show member pathways
12 GP9 ITGA2 ITGA2B ITGB3
8 11.99 ITGA2 ITGA2B ITGB3
9 11.95 FCGR2A FCGR2B FCGR2C ITGA2 ITGB3
10
Show member pathways
11.9 FCGR2A FCGR2B FCGR2C
11
Show member pathways
11.9 ITGA2 ITGA2B ITGB3
12 11.89 FCGR2A FCGR2B FCGR2C ITGB3
13 11.87 FCGR2A FCGR2C SELP
14 11.81 FCGR2A GP9 ITGA2 ITGA2B ITGB3
15 11.8 CD19 ITGA2 ITGA2B ITGB3
16 11.69 FCGR2A ITGA2 ITGA2B ITGB3
17
Show member pathways
11.65 GP9 ITGA2B ITGB3 MPL THPO
18 11.59 ITGA2 ITGA2B ITGB3 THPO
19 11.52 ITGA2 ITGA2B ITGB3
20 11.49 CD19 ITGA2 ITGA2B ITGB3
21 11.48 FCGR2A FCGR2B FCGR2C SELP
22 11.44 FCGR2A ITGA2B ITGB3
23 11.42 ITGA2 ITGA2B ITGB3 MYH9
24 11.42 CD19 GP9 ITGA2 ITGA2B ITGB3 THPO
25 11.41 GP9 ITGA2 ITGA2B ITGB3
26 11.4 GP9 ITGA2B ITGB3
27 11.4 FCGR2A FCGR2B FCGR2C IL17A ITGB3
28 11.23 CD19 FCGR2A ITGA2 ITGA2B ITGB3 MPL
29 11.07 ITGA2B ITGB3
30 10.96 ITGA2B ITGB3
31 10.89 IL17A ITGA2 ITGA2B ITGB3 THPO
32 10.72 GP9 ITGA2

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.88 CD19 FCGR2B GP9 ITGB3 MPL SELP
2 focal adhesion GO:0005925 9.67 ITGA2 ITGA2B ITGB3 MYH9
3 integrin complex GO:0008305 9.33 ITGA2 ITGA2B ITGB3
4 platelet alpha granule membrane GO:0031092 9.13 ITGA2B ITGB3 SELP
5 external side of plasma membrane GO:0009897 9.1 CD19 FCGR2B IL17A ITGA2 ITGA2B SELP
6 integral component of membrane GO:0016021 10.06 CD19 FCGR2A FCGR2B FCGR2C FCGRT GP9
7 plasma membrane GO:0005886 10.03 CD19 FCGR2A FCGR2B FCGR2C FCGRT GP9

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.8 FCGR2B FCGR2C FCGRT IL17A
2 cell adhesion GO:0007155 9.73 GP9 ITGA2 ITGA2B ITGB3 MYH9 SELP
3 platelet degranulation GO:0002576 9.61 ITGA2B ITGB3 SELP
4 cell-matrix adhesion GO:0007160 9.54 ITGA2 ITGA2B ITGB3
5 cell adhesion mediated by integrin GO:0033627 9.48 ITGA2 ITGB3
6 cell-substrate adhesion GO:0031589 9.46 ITGA2 ITGB3
7 integrin-mediated signaling pathway GO:0007229 9.46 ITGA2 ITGA2B ITGB3 MYH9
8 mesodermal cell differentiation GO:0048333 9.4 ITGA2 ITGB3
9 thrombopoietin-mediated signaling pathway GO:0038163 9.32 MPL THPO
10 positive regulation of leukocyte migration GO:0002687 9.13 ITGA2 ITGA2B SELP
11 platelet aggregation GO:0070527 8.92 ITGA2B ITGB3 MPL MYH9

Molecular functions related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.33 ITGA2 ITGB3 MYH9
2 extracellular matrix binding GO:0050840 9.26 ITGA2B ITGB3
3 fibrinogen binding GO:0070051 8.96 ITGA2B ITGB3
4 IgG binding GO:0019864 8.92 FCGR2A FCGR2B FCGR2C FCGRT

Sources for Thrombocytopenia Due to Platelet Alloimmunization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....